72.19.Z - Other research and experimental development on natural sciences and engineering
46.45.Z - Wholesale of perfume and cosmetics
46.46.Z - Wholesale of pharmaceutical goods
47.74.Z - Retail sale of medical and orthopaedic goods in specialised stores
47.91.Z - Retail sale via mail order houses or via Internet
71.20.B - Other technical testing and analysis
72.11.Z - Research and experimental development on biotechnology
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
77.40.Z - Leasing of intellectual property and similar products, except copyrighted works
86.90.D - Paramedical activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Assets | 274,5 | 265,3 | 254,9 | -3,9 |
Gross profit (loss) | -57,4 | -54,3 | -38,1 | 29,9 |
EBITDA | -27,6 | -41,3 | -33,5 | 19 |
Net profit (loss) | -57,4 | -54,3 | -38,1 | 29,9 |
Cash | 3,4 | 5,8 | 0 | -100 |
Net income from sale | 13,2 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 28,5 | 73,5 | 101,2 | 37,6 |
Short time liabilities | 28,5 | 73,5 | 101,2 | 37,6 |
Working assets | 225,7 | 229,5 | 223,6 | -2,5 |
Equity capital | 246 | 191,8 | 153,7 | -19,9 |
Operating profit (EBIT) | -57,4 | -54,3 | -38,1 | 29,9 |
Depreciation | 29,8 | 13 | 4,6 | -64,7 |
% | % | % | p.p. | |
Profitability of capital | -23,3 | -28,3 | -24,8 | 3,5 |
Equity capital to total assets | 89,6 | 72,3 | 60,3 | -12 |
Gross profit margin | -434,8 | 26,3 | ||
EBITDA Margin | -209,2 | -194,7 | ||
Days | Days | Days | Days | |
Short term commitment turnover cycle | 787 | 2 147 483 648 | 2 147 483 648 | 0 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane